BridgeBio Oncology Therapeutics, Inc. (BBOT) Stock
Healthcare · Biotechnology · Member of Other US Stocks
BridgeBio Oncology Therapeutics, Inc. (BBOT) closed at USD 2.90 on 2026-10-14, a change of -74.2 % over the past year, with a market capitalization of USD 236.51M.
BridgeBio Oncology Therapeutics, Inc. recent closing prices
| Date | Close (USD) |
|---|---|
| 2026-10-14 | 2.90 |
| 2026-10-13 | 2.95 |
| 2026-10-12 | 3.26 |
| 2026-10-09 | 3.31 |
| 2026-10-08 | 3.42 |
| 2026-10-07 | 3.44 |
| 2026-10-06 | 3.50 |
The most recent trading day is not shown. For full charts and indicators use the analysis page.
BridgeBio Oncology Therapeutics, Inc. key figures
- Previous close
- USD 2.90 (2026-10-14)
- 1-year change
- -74.2 %
- Market cap
- USD 236.51M
- Enterprise value
- USD 13.32M
- P/E ratio (trailing)
- -42.14
- P/E ratio (forward)
- -1.09
- EPS (trailing)
- -0.07
- EPS (forward)
- -2.72
- PEG ratio
- n/a
- Price to book
- 0.73
- Revenue growth
- n/a
- Earnings growth
- n/a
- Dividend per share (trailing)
- 0.00
- Short ratio
- 4.72
- Employees
- 88
- Analyst consensus (third-party)
- none
Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.
About BridgeBio Oncology Therapeutics, Inc.
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.
Technical indicators and comparison
Show RSI, MACD, EMA, CCI and ADX for BridgeBio Oncology Therapeutics, Inc. and compare it with other stocks.
Analyze BBOTAll Other US Stocks stocksStock-scoring.com provides this page for information only. It is not investment advice or a recommendation to buy or sell BridgeBio Oncology Therapeutics, Inc. shares.